You can filter the data below or go straight to the results. Descriptions of the various cell types we distribute, such as CPLs and LCLs, can be found here. Note that CPLs are ideal for creating iPSCs. Information on ordering biomaterials can be found here.
To share these results with others, including any filters applied, click the box below to copy a link to this page to your clipboard:
Cell type descriptions (LCLs, CPLs, etc) can be found here.
Distribution | Subjects | With DNA | Plasma | LCLs | CPLs | Whole Blood |
---|---|---|---|---|---|---|
Cannabis 1.0 | 201 |
201 (100%) |
0 ( 0%) |
0 ( 0%) |
0 ( 0%) |
199 (99%) |
Cocaine Dependence 3.0 | 2,443 |
1,568 (64%) |
95 ( 4%) |
1,155 (47%) |
1,485 (61%) |
133 ( 5%) |
Nicotine Dependence 11.0 | 15,593 |
13,230 (85%) |
2,467 (16%) |
7,716 (49%) |
12,636 (81%) |
4,658 (30%) |
Opioid Dependence 5.7 | 7,971 |
6,556 (82%) |
2 ( 0%) |
3,189 (40%) |
4,240 (53%) |
3,860 (48%) |
Opioid-Cocaine Dependence 2.1 | 7,007 |
5,344 (76%) |
0 ( 0%) |
2,128 (30%) |
4,922 (70%) |
2,879 (41%) |
Polysubstance Dependence 4.0 | 4,453 |
3,465 (78%) |
3 ( 0%) |
2,004 (45%) |
3,365 (76%) |
1,814 (41%) |
Total | 37,668 |
30,364 (81%) |
2,567 ( 7%) |
16,192 (43%) |
26,648 (71%) |
13,543 (36%) |
Item | Value |
---|---|
Subjects | 37,668 |
With DNA | 30,364 (81%) |
Instrument: DSM-IV | 23,853 (63%) |
Instrument: DSM-III-R | 1,028 (3%) |
Instrument: Unknown | 12,787 (34%) |
Females / Males / Unknown | 17,737 (47%) / 19,880 (53%) / 51 (0%) |
Age | Average: 39.9, Min: 11, Max: 111 |
Race: White | 18,714 (50%) |
Race: African-American | 11,192 (30%) |
Race: Hispanic | 2,097 (6%) |
Race: Missing | 234 (1%) |
Race: American Indian | 45 (0%) |
Race: Asian | 2,030 (5%) |
Race: Pac Islander | 3 (0%) |
Race: Other | 3,353 (9%) |
Cell type descriptions (LCLs, CPLs, etc) can be found here.
Cell Type | Subjects |
---|---|
LCL | 16,192 (43%) |
CPL | 26,648 (71%) |
LCL gDNA | 15,752 (42%) |
WB gDNA | 16,420 (44%) |
Plasma | 2,567 ( 7%) |
Whole Blood | 13,543 (36%) |
Disease | Affected | Unaffected | Other |
---|---|---|---|
Opioid Dependence | 8,304 (22%) |
13,675 (36%) |
15,689 (42%) |
Cocaine Dependence | 8,318 (22%) |
15,135 (40%) |
14,215 (38%) |
Alcohol Dependence | 5,983 (16%) |
14,326 (38%) |
17,359 (46%) |
Nicotine Dependence | 9,146 (24%) |
6,826 (18%) |
21,696 (58%) |
Cannabis Dependence | 4,512 (12%) |
13,421 (36%) |
19,735 (52%) |
Stimulant Dependence | 1,454 ( 4%) |
12,335 (33%) |
23,879 (63%) |
Sedative Dependence | 1,063 ( 3%) |
12,189 (32%) |
24,416 (65%) |
Other Drug Dependence | 1,035 ( 3%) |
14,410 (38%) |
22,223 (59%) |
Opioid Abuse | 1,202 ( 3%) |
10,912 (29%) |
25,554 (68%) |
Cocaine Abuse | 1,285 ( 3%) |
10,335 (27%) |
26,048 (69%) |
Alcohol Abuse | 2,971 ( 8%) |
9,019 (24%) |
25,678 (68%) |
Cannabis Abuse | 2,130 ( 6%) |
9,382 (25%) |
26,156 (69%) |
Stimulant Abuse | 278 ( 1%) |
8,848 (23%) |
28,542 (76%) |
Sedative Abuse | 324 ( 1%) |
8,395 (22%) |
28,949 (77%) |
Other Drug Abuse | 460 ( 1%) |
7,843 (21%) |
29,365 (78%) |
Cell type descriptions (LCLs, CPLs, etc) can be found here.
Study | Name | PI | Subjects | With DNA | Plasma | LCLs | CPLs | Whole Blood |
---|---|---|---|---|---|---|---|---|
32 | Achieving Cannabis Cessation-Evaluation of N-Acetylcysteine (ACCENT); CTN-0053 | Kevin Gray | 201 |
201 (100%) |
0 ( 0%) |
0 ( 0%) |
0 ( 0%) |
199 (99%) |
Total | 201 |
201 (100%) |
0 ( 0%) |
0 ( 0%) |
0 ( 0%) |
199 (99%) |
Study | Name | PI | Subjects | With DNA | Plasma | LCLs | CPLs | Whole Blood |
---|---|---|---|---|---|---|---|---|
7 | An Introduction to the Family Study of Cocaine | Laura Bierut | 1,914 |
1,049 (55%) |
95 ( 5%) |
852 (45%) |
990 (52%) |
103 ( 5%) |
13 | Genetics of Cocaine Induced Psychosis | Joseph F. Cubells | 249 |
241 (97%) |
0 ( 0%) |
239 (96%) |
224 (90%) |
1 ( 0%) |
29 | Genetics Protocol of the Cocaine Use Reduction with Buprenorphine (CURB) Study; CTN-0048 | David A. Nielsen | 280 |
278 (99%) |
0 ( 0%) |
64 (23%) |
271 (97%) |
29 (10%) |
Total | 2,443 |
1,568 (64%) |
95 ( 4%) |
1,155 (47%) |
1,485 (61%) |
133 ( 5%) |
Study | Name | PI | Subjects | With DNA | Plasma | LCLs | CPLs | Whole Blood |
---|---|---|---|---|---|---|---|---|
NicSNP | The NicSNP Study | Laura Bierut | 1,927 |
1,927 (100%) |
515 (27%) |
1,340 (70%) |
1,878 (97%) |
772 (40%) |
2 | Mapping Susceptibility Genes for Nicotine Dependence | Ming D. Li | 2,803 |
1,962 (70%) |
0 ( 0%) |
1,961 (70%) |
1,837 (66%) |
148 ( 5%) |
6 | The Genetics of Vulnerability to Nicotine | Pamela Madden | 3,446 |
2,344 (68%) |
0 ( 0%) |
2,330 (68%) |
2,156 (63%) |
30 ( 1%) |
9 | Differentiation of Phenotypes for Smoking: Administrative Supplement to Join NIDA Genetics Consortium | Ovide Pomerleau | 1,565 |
1,540 (98%) |
0 ( 0%) |
607 (39%) |
1,502 (96%) |
887 (57%) |
10 | Pharmacokinetics of Nicotine in Twins | Gary Swan | 124 |
62 (50%) |
0 ( 0%) |
62 (50%) |
60 (48%) |
0 ( 0%) |
15 | Nicotine Dependence | Laura Bierut | 2,146 |
1,813 (84%) |
876 (41%) |
854 (40%) |
1,760 (82%) |
1,131 (53%) |
16 | Nicotine Dependence | Mark Leppert | 917 |
917 (100%) |
2 ( 0%) |
359 (39%) |
821 (90%) |
535 (58%) |
27 | The Genetic Study of Nicotine Dependence in African Americans (AAND) | Laura Bierut | 1,792 |
1,792 (100%) |
206 (11%) |
194 (11%) |
1,753 (98%) |
1,134 (63%) |
35 | Genetically Informative Smoking Cessation Trial | Li-Shiun Chen | 873 |
873 (100%) |
868 (99%) |
9 ( 1%) |
869 (100%) |
21 ( 2%) |
Total | 15,593 |
13,230 (85%) |
2,467 (16%) |
7,716 (49%) |
12,636 (81%) |
4,658 (30%) |
Study | Name | PI | Subjects | With DNA | Plasma | LCLs | CPLs | Whole Blood |
---|---|---|---|---|---|---|---|---|
3 | Molecular Genetics of Heroin Dependence in China | Ming Tsuang | 1,929 |
1,232 (64%) |
0 ( 0%) |
1,097 (57%) |
3 ( 0%) |
222 (12%) |
5 | Addictions, Genotypes, Polymorphisms, and Function | Mary Jeanne Kreek | 1,751 |
1,751 (100%) |
2 ( 0%) |
768 (44%) |
1,708 (98%) |
1,012 (58%) |
14 | Genome-Wide Analysis for Addiction Susceptibility Genes | Herb Lachman | 1,405 |
693 (49%) |
0 ( 0%) |
598 (43%) |
640 (46%) |
116 ( 8%) |
17 | Opioid Dependence | Wade Berrettini | 204 |
200 (98%) |
0 ( 0%) |
70 (34%) |
191 (94%) |
99 (49%) |
18 | Opioid Dependence: Candidate Genes and G x E Effects | Elliot Nelson | 1,896 |
1,895 (100%) |
0 ( 0%) |
500 (26%) |
954 (50%) |
1,627 (86%) |
24 | START Pharmacogenetics: Exploratory Genetic Studies in Starting Treatment with Agonist Replacement Therapies (START) | Wade Berrettini | 786 |
785 (100%) |
0 ( 0%) |
156 (20%) |
744 (95%) |
784 (100%) |
Total | 7,971 |
6,556 (82%) |
2 ( 0%) |
3,189 (40%) |
4,240 (53%) |
3,860 (48%) |
Study | Name | PI | Subjects | With DNA | Plasma | LCLs | CPLs | Whole Blood |
---|---|---|---|---|---|---|---|---|
1 | Genetics of Opioid Dependence | Joel Gelernter | 6,511 |
4,848 (74%) |
0 ( 0%) |
2,118 (33%) |
4,705 (72%) |
2,785 (43%) |
20 | Innovative Approaches for Cocaine Pharmacotherapy | Henry Kranzler | 496 |
496 (100%) |
0 ( 0%) |
10 ( 2%) |
217 (44%) |
94 (19%) |
Total | 7,007 |
5,344 (76%) |
0 ( 0%) |
2,128 (30%) |
4,922 (70%) |
2,879 (41%) |
Study | Name | PI | Subjects | With DNA | Plasma | LCLs | CPLs | Whole Blood |
---|---|---|---|---|---|---|---|---|
11 | Adolescent Drug Dependence | John Hewitt | 2,403 |
1,589 (66%) |
1 ( 0%) |
1,084 (45%) |
1,521 (63%) |
502 (21%) |
12 | Substance Abuse and the Dopamine System Genes | Michael M. Yanyukov | 600 |
470 (78%) |
0 ( 0%) |
406 (68%) |
449 (75%) |
0 ( 0%) |
19 | Epidemiological Study of Substance Abuse | Rob Philibert | 562 |
520 (93%) |
1 ( 0%) |
485 (86%) |
510 (91%) |
430 (77%) |
23 | Substance Use Disorder Liability: Candidate Gene System | Michael M. Vanyukov | 888 |
886 (100%) |
1 ( 0%) |
29 ( 3%) |
885 (100%) |
882 (99%) |
Total | 4,453 |
3,465 (78%) |
3 ( 0%) |
2,004 (45%) |
3,365 (76%) |
1,814 (41%) |
cell_file
version: 2023-11-14 #2